GGrantIndex
← Leaderboards

Patricia I Dickson

Lundquist Institute For Biomedical Innovation At Harbor-Ucla Medical Center

$15,605,304
Attributed
$24,934,735
Total exposure
21
Grants
20
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $4.3M · FY200625
$5M$3.8M$2.5M$1.3M$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$24,480,683 · 20
FDA$454,052 · 1

By mechanism

R01$6,835,460 · 5
U44$5,612,276 · 1
RM1$4,754,001 · 1
U01$4,626,862 · 3
T32$816,790 · 1
R21$782,811 · 2

Top collaborators

Most similar at Lundquist Institute For Biomedical Innovation At Harbor-Ucla Medical Center

Same institution · by research overlap

Others in their field

Top investigators on “Enzymes

Research focus

EnzymesCellsBrainEnzyme Replacement TherapyPreventGlycosaminoglycansCanis FamiliarisChildMucopolysaccharidosis IGenesClinical TrialsCerebrospinal FluidSuccessSiteImpairmentBiochemicalAffectPhenotypeProteinsAdultChildhoodLysosomal Storage DiseasesLeadMucopolysaccharidoses

Grant awards (55)

Systems-Level Approach to Neuronopathic Lysosomal Storage Disorders$1,590,711
RM1 · FY2025 · NS · contact PI
Washington University in St. Louis UDN Diagnostic Center of Excellence$723,751
U01 · FY2025 · NS · contact PI
Cellular Phenotypes of Genetic Variants in Mucopolysaccharidosis$450,047
R01 · FY2025 · NS · contact PI
Postdoctoral Training Program in Genomic Medicine$191,807
T32 · FY2025 · GM · contact PI
Systems-Level Approach to Neuronopathic Lysosomal Storage Disorders$1,558,704
RM1 · FY2024 · NS · contact PI
Washington University in St. Louis UDN Diagnostic Center of Excellence$753,897
U01 · FY2024 · NS · contact PI
Cellular Phenotypes of Genetic Variants in Mucopolysaccharidosis$436,544
R01 · FY2024 · NS · contact PI
Postdoctoral Training Program in Genomic Medicine$186,487
T32 · FY2024 · GM · contact PI
Systems-Level Approach to Neuronopathic Lysosomal Storage Disorders$1,604,586
RM1 · FY2023 · NS · contact PI
Washington University School of Medicine Undiagnosed Diseases Network Clinical Site$623,335
U01 · FY2023 · NS · contact PI
Cellular Phenotypes of Genetic Variants in Mucopolysaccharidosis$451,478
R01 · FY2023 · NS · contact PI
Washington University School of Medicine Undiagnosed Diseases Network Clinical Site$311,000
U01 · FY2023 · NS · contact PI
Postdoctoral Training Program in Genomic Medicine$182,022
T32 · FY2023 · GM · contact PI
Cellular phenotype of mucopolysaccharidosis II for studies of genomic variants$78,750
R03 · FY2023 · NS · contact PI
Development and Validation of Therapy for Mucopolysaccharidosis III$2,435,870
U44 · FY2022 · NS
Recombinant alpha-N-acetylglucosaminidase with improved mannose 6-phosphorylation for treatment of Sanfilippo B syndrome$644,183
R33 · FY2022 · NS · contact PI
Intravenous delivery of 2-hydroxypropyl-Beta-cyclodextrin for treatment of Niemann-Pick C disease$519,342
U01 · FY2022 · HD · contact PI
WASHINGTON UNIVERSITY SCHOOL OF MEDICINE UNDIAGNOSED DISEASES NETWORK CLINICAL SITE$476,195
U01 · FY2022 · HG · contact PI
Postdoctoral Training Program in Genomic Medicine$177,387
T32 · FY2022 · GM · contact PI
Cellular phenotype of mucopolysaccharidosis II for studies of genomic variants$78,750
R03 · FY2022 · NS · contact PI
Washington University School of Medicine Undiagnosed Diseases Network Clinical Site$550,000
U01 · FY2021 · HG · contact PI
Gene therapy with modified GlcNAc-1-phosphotransferase for mucolipidosis$433,125
R21 · FY2021 · NS · contact PI
WASHINGTON UNIVERSITY SCHOOL OF MEDICINE UNDIAGNOSED DISEASES NETWORK CLINICAL SITE$150,000
U01 · FY2021 · HG · contact PI
Postdoctoral Training Program in Genomic Medicine$79,087
T32 · FY2021 · GM · contact PI
Recombinant alpha-N-acetylglucosaminidase with improved mannose 6-phosphorylation for treatment of Sanfilippo B syndrome$536,569
R61 · FY2020 · NS · contact PI
Intravenous delivery of 2-hydroxypropyl-Beta-cyclodextrin for treatment of Niemann-Pick C disease$519,342
U01 · FY2019 · HD · contact PI
Phenotypic Effects of Brain-Directed Enzyme Therapy for Sanfilippo B Syndrome$394,812
R01 · FY2019 · NS · contact PI
Development and validation of therapy for mucopolysaccharidosis III$3,176,406
U44 · FY2018 · NS
Phenotypic effects of brain-directed enzyme therapy for Sanfilippo B syndrome$170,004
R01 · FY2018 · NS · contact PI
Phenotypic effects of brain-directed enzyme therapy for Sanfilippo B syndrome$140,279
R01 · FY2018 · NS · contact PI
Phenotypic effects of brain-directed enzyme therapy for Sanfilippo B syndrome$310,283
R01 · FY2017 · NS · contact PI
Neuroimaging and Neuropathology of Mucopolysaccharidosis I$304,460
R01 · FY2017 · NS · contact PI
Phenotypic effects of brain-directed enzyme therapy for Sanfilippo B syndrome$100,000
R01 · FY2017 · NS · contact PI
Phenotypic effects of brain-directed enzyme therapy for Sanfilippo B syndrome$310,283
R01 · FY2016 · NS · contact PI
Neuroimaging and Neuropathology of Mucopolysaccharidosis I$304,460
R01 · FY2016 · NS · contact PI
Phenotypic effects of brain-directed enzyme therapy for Sanfilippo B syndrome$324,021
R01 · FY2015 · NS · contact PI
Neuroimaging and Neuropathology of Mucopolysaccharidosis I$304,460
R01 · FY2015 · NS · contact PI
Neuroimaging and Neuropathology of Mucopolysaccharidosis I$301,415
R01 · FY2014 · NS · contact PI
The humoral immune response to recombinant enzyme in mucopolysaccharidosis I$61,569
R03 · FY2014 · HD · contact PI
Neuroimaging and Neuropathology of Mucopolysaccharidosis I$47,656
R01 · FY2014 · NS · contact PI
Neuroimaging and Neuropathology of Mucopolysaccharidosis I$304,460
R01 · FY2013 · NS · contact PI
Glycosylation-independent enzyme therapy of the brain in Sanfilippo B syndrome$184,006
R21 · FY2013 · NS · contact PI
The humoral immune response to recombinant enzyme in mucopolysaccharidosis I$63,343
R03 · FY2013 · HD · contact PI
Glycosylation-independent enzyme therapy of the brain in Sanfilippo B syndrome$165,680
R21 · FY2012 · NS · contact PI
Intrathecal enzyme therapy for mucopolysaccharidosis I$350,323
R01 · FY2010 · NS · contact PI
Intrathecal enzyme therapy for mucopolysaccharidosis I$347,748
R01 · FY2009 · NS · contact PI
Pilot/Phase I Study of Intrathecal Laronidase for Spinal Cord Compression in Muco$229,419
R01 · FY2009 · FD · contact PI
A STUDY OF INTRATHECAL ENZYME REPLACEMENT THERAPY FOR SPINAL CORD COMPRESSION$11,635
M01 · FY2009 · RR · contact PI
Intrathecal enzyme therapy for mucopolysaccharidosis I$339,787
R01 · FY2008 · NS · contact PI
Pilot/Phase I Study of Intrathecal Laronidase for Spinal Cord Compression in Muco$224,633
R01 · FY2008 · FD · contact PI
CLINICAL TRIAL: A STUDY OF INTRATHECAL ENZYME REPLACEMENT THERAPY FOR SPINAL COR$23,902
M01 · FY2008 · RR · contact PI
Intrathecal enzyme therapy for mucopolysaccharidosis I$345,515
R01 · FY2007 · NS · contact PI
A STUDY OF INTRATHECAL ENZYME REPLACEMENT THERAPY FOR SPINAL CORD COMPRESSION$4,717
M01 · FY2007 · RR · contact PI
Intrathecal enzyme therapy for mucopolysaccharidosis I$343,373
R01 · FY2006 · NS · contact PI
A STUDY OF INTRATHECAL ENZYME REPLACEMENT THERAPY FOR SPINAL CORD COMPRESSION$3,117
M01 · FY2006 · RR · contact PI